VK2735 for Weight Management Phase 2 (Venture Oral Dosing)

Launched by VIKING THERAPEUTICS, INC. · Feb 10, 2025

Keywords

ClinConnect Summary

This clinical trial is studying a new medication called VK2735 to see if it can help adults with obesity or overweight lose weight safely and effectively. The trial will last for 13 weeks and will involve giving participants either VK2735 or a placebo (a pill that looks the same but has no active medication) once a day. Researchers want to find out how well the medication works, how it affects the body, and if there are any side effects.

To be eligible for the trial, participants must be at least 18 years old and have a body mass index (BMI) of 30 or higher, or a BMI of 27 or higher if they also have a weight-related health issue like high blood pressure or sleep apnea. Participants should not have had significant weight changes recently or certain health conditions like diabetes or pancreatitis. If you join the trial, you'll be monitored closely throughout the study, and you'll receive regular check-ups to ensure your safety. This study is currently looking for participants, and all genders are welcome to apply.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Age ≥18 years of age at the time of signing the informed consent.
• • 2. Body mass index (BMI) ≥30 kg/m2 OR ≥27 kg/m2 with at least one weight-related co-morbid condition (treated or untreated), and BMI \<50 kg/m2
• • Weight-related co-morbid conditions include hypertension, dyslipidemia, obstructive sleep apnea or cardiovascular disease.
• • BMI calculated at the Screening visit will be used to determine eligibility.
• Exclusion Criteria:
• • 1. History of or current clinically significant medical or psychiatric disorder that, in the opinion of the Investigator, does not support study participation
• • 2. Self-reported body weight change of 5% or more within 3 months of screening
• • 3. Current or past diagnosis of diabetes mellitus (including type 1, type 2, gestational)
• • 4. Current or past diagnosis of chronic pancreatitis
• • 5. Calcitonin ≥50 ng/L measured by central laboratory at screening (individuals with elevated calcitonin at initial screening may be re-screened)
• • 6. Any GLP-1 receptor agonist or GLP-1/GIP dual agonist within 6 months of Screening
• • 7. Any prescription or over-the-counter medications intended for weight loss within 6 months of screening